LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC (www.Goldberglawpc.com) reminds investors in IsoRay, Inc. (“IsoRay” or the “Company”) (NYSE: ISR), who purchased or otherwise acquired shares between May 20, 2015 and May 21, 2015, inclusive (the “Class Period”), of the July 21, 2015 deadline to file a motion to be appointed as lead plaintiff.
If you are a shareholder who suffered a loss during the Class Period, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
IsoRay manufactures isotope-based medical products for the treatment of cancer and other malignant diseases. The Company produces Proxcelan Cesium-131 brachytherapy seeds for the treatment of various cancers. According to the complaint, on May 20, 2015, the Company issued a press release touting the publication of the first major peer reviewed study of Cecium-131 seeds for the treatment of non-small cell lung cancers. However, on May 21, 2015, TheStreet.com published an article claiming that IsoRay selectively edited findings from the study, making the product appear better than it was. The author of the article, Adam Feuerstein, stated that he did not consider the results of the study to be “outstanding.” As a result of this news, shares of IsoRay fell over 35% on May 21, 2015, to close at $2.02 per share.
If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, via email at info@goldberglawpc.com, or visit our website at Goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
